Mitochondrial Membrane Fluidity is Consistently Increased in Different Models of Huntington Disease: Restorative Effects of Olesoxime
- 18 March 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Neurobiology
- Vol. 50 (1), 107-118
- https://doi.org/10.1007/s12035-014-8663-3
Abstract
Huntington disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the huntingtin gene (HTT). One prominent target of the mutant huntingtin protein (mhtt) is the mitochondrion, affecting its morphology, distribution, and function. Thus, mitochondria have been suggested as potential therapeutic targets for the treatment of HD. Olesoxime, a cholesterol-like compound, promotes motor neuron survival and neurite outgrowth in vitro, and its effects are presumed to occur via a direct interaction with mitochondrial membranes (MMs). We examined the properties of MMs isolated from cell and animal models of HD as well as the effects of olesoxime on MM fluidity and cholesterol levels. MMs isolated from brains of aged Hdh Q111/Q111 knock-in mice showed a significant decrease in 1,6-diphenyl-hexatriene (DPH) anisotropy, which is inversely correlated with membrane fluidity. Similar increases in MM fluidity were observed in striatal STHdh Q111/Q111 cells as well as in MMs isolated from brains of BACHD transgenic rats. Treatment of STHdh cells with olesoxime decreased the fluidity of isolated MMs. Decreased membrane fluidity was also measured in olesoxime-treated MMs isolated from brains of HD knock-in mice. In both models, treatment with olesoxime restored HD-specific changes in MMs. Accordingly, olesoxime significantly counteracted the mhtt-induced increase in MM fluidity of MMs isolated from brains of BACHD rats after 12 months of treatment in vivo, possibly by enhancing MM cholesterol levels. Thus, olesoxime may represent a novel pharmacological tool to treat mitochondrial dysfunction in HD.Keywords
This publication has 94 references indexed in Scilit:
- Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's diseaseMolecular and Cellular Neuroscience, 2012
- Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxelNeuroscience, 2012
- Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activityNature Medicine, 2011
- Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuliEMBO Molecular Medicine, 2010
- Altered cholesterol and fatty acid metabolism in Huntington diseaseJournal of Clinical Lipidology, 2010
- Mitochondria: A therapeutic target in neurodegenerationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxelPain, 2009
- Mitochondrial structural and functional dynamics in Huntington's diseaseBrain Research Reviews, 2009
- The interaction of beta-amyloid protein with cellular membranes stimulates its own productionBiochimica et Biophysica Acta (BBA) - Biomembranes, 2009
- Mitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature, 2006